Novartis Acquires Tourmaline Bio for $1.4B • Deal Value: $1.4 billion (fully diluted basis) • Offer Price: $48 per share • Structure: Merger of Novartis acquiring subsidiary into Tourmaline Bio • Expected Closing: Q4 2025 • Strategic Fit: Strengthens
